Harvoni® Uses and Dosage India

Harvoni® Uses and Dosage India

Harvoni® is a medicine which is made with the combination of ledipasvir and sofosbuvir. This is a medicine which is used to cure hepatitis. But you can take this medicine only after concerning with your doctor. Before using this medicine you are frequently needed concern with your doctor.

How to Use this Medicine:

There are certain points which you have to keep in mind before using this medicine. There is a reason why this is important to follow the prescription before taking this medicine.

Harvoni® is sometimes taken with another medicine called ribavirin. This ribavirin can cause birth defects or death in an unborn baby. So while taking this medicine you are suggested to concern with your Doctor. You should not use harvoni® with ribavirin if you are suffering from these problems:

  • Severe kidney disease
  • A hemoglobin blood cell disorders such as sickle-cell anemia
  • If you are pregnant
  • If you are a man and your partner is pregnant

Harvoni® Dosage Information:

Usual Adult Dose for Chronic Hepatitis C
1 tablet orally once a day
Duration of therapy: Here are some therapies which are with cirrhosis or without cirrhosis. These therapies have applied the patients which are native as well as experienced. Duration of this therapy may be 12 weeks or 24 weeks.

While taking harvoni® you have to avoid an antacid within 4 hours before or 4 hours after you take Harvoni®. Taking Harvoni® will not prevent you from passing hepatitis C to other people. If you are allergic you have to take this medicine by concern with your doctor.
Drugs which can affect Harvoni®

  • Amiodarone
  • Ribavirin
  • Atripla (efavirenz, emtricitabine, and tenofovir)
  • Rosuvastatin (Crestor)
  • Digoxin (digitalis)
  • Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir

If you observe any sign of allergic reaction you can immediately medical help from our medical facilities.

Leave a Reply

Your email address will not be published. Required fields are marked *

*